Potent dendritic-cell cancer vaccines could be used to induce functional antitumour immunity without off-target toxicity.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Development of dendritic cell loaded MAGE-A2 long peptide; a potential target for tumor-specific T cell-mediated prostate cancer immunotherapy
Cancer Cell International Open Access 11 November 2023
-
Biomimetic nanovaccine-mediated multivalent IL-15 self-transpresentation (MIST) for potent and safe cancer immunotherapy
Nature Communications Open Access 24 October 2023
-
Rescue of dendritic cells from glycolysis inhibition improves cancer immunotherapy in mice
Nature Communications Open Access 02 September 2023
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 digital issues and online access to articles
$99.00 per year
only $8.25 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Rezvani, K., Rouce, R., Liu, E. & Shpall, E. Mol. Therapy 25, 1769–1781 (2017).
D’Aloia, M. M., Zizzari, I. G., Sacchetti, B., Pierelli, L. & Alimandi, M. Cell Death Dis. 9, 282 (2018).
Cheever, M. A. & Higano, C. S. Clin. Cancer Res. 17, 3520–3526 (2011).
Leaf, R. K. et al. J. Immunotherapy 40, 315–322 (2017).
Doebel, T., Voisin, B. & Nagao, K. Trends Immunol. 38, 817–828 (2017).
Villani, A. C. et al. Science 356, eaah4573 (2017).
Alcantara-Hernandez, M. et al. Immunity 47, 1037–1050.e6 (2017).
Palucka, K. & Banchereau, J. Immunity 39, 38–48 (2013).
Rosenblatt, J. et al. Sci. Transl. Med. 8, 368ra171 (2016).
Van Tendeloo, V. F. et al. Proc. Natl Acad. Sci. USA 107, 13824–13829 (2010).
Schreibelt, G. et al. Clin. Cancer Res. 22, 2155–2166 (2016).
Saxena, M. & Bhardwaj, N. Trends Cancer 4, 119–137 (2018).
Garg, A. D. et al. Oncoimmunology 6, e1328341 (2017).
Anguille, S., Smits, E. L., Lion, E., van Tendeloo, V. F. & Berneman, Z. N. The Lancet Oncology 15, e257–e267 (2014).
Saxena, M. & Bhardwaj, N. Curr. Opin. Immunol. 47, 35–43 (2017).
Van Lint, S. et al. Cancer Immunol. Res. 4, 146–156 (2016).
Van der Jeught, K. et al. Oncotarget 6, 1359–1381 (2015).
Hutten, T. J. et al. J. Immunol. 197, 2715–2725 (2016).
Goyvaerts, C. et al. Oncotarget 5, 704–715 (2014).
Manches, O. et al. Haematologica 90, 625–634 (2005).
Kranz, L. M. et al. Nature 534, 396–401 (2016).
De Vries, J. & Figdor, C. I. Nature 534, 329–331 (2016).
Hartung, E. et al. J. Immunol. 194, 1069–1079 (2015).
Cauwels, A. et al. Cancer Res. 78, 463–474 (2018).
De Munck, J., Binks, A., McNeish, I. A. & Aerts, J. L. J. Leukocyte Biol. 102, 631–643 (2017).
Harrington, K. J. et al. Expert Rev. Anticancer Therapy 15, 1389–1403 (2015).
van den Bijgaart, R. J. et al. Cancer Immunol. Immunotherapy 66, 247–258 (2017).
Pardi, N., Hogan, M. J., Porter, F. W. & Weissman, D. Nat. Rev. Drug Discov. 17, 261–279 (2018).
Sabado, R. L., Balan, S. & Bhardwaj, N. Cell Res. 27, 74–95 (2017).
Prue, R. L. et al. J. Immunotherapy 38, 71–76 (2015).
Tel, J. et al. Cancer Res. 73, 1063–1075 (2013).
Balan, S., Finnigan, J. & Bhardwaj, N. Cancer J. 23, 131–137 (2017).
Carreno, B. M. et al. Science 348, 803–808 (2015).
Chiang, C. L. et al. Clin. Cancer Res. 19, 4801–4815 (2013).
Van Lint, S. et al. Cancer Immunol. Immunotherapy 63, 959–967 (2014).
Sundarasetty, B. S. et al. Gene Therapy 22, 707–720 (2015).
Squadrito, M. L., Cianciaruso, C., Hansen, S. K. & De Palma, M. Nat. Methods 15, 183–186 (2018).
Balan, S. & Dalod, M. Methods Mol. Biol. 1423, 19–37 (2016).
Yewdall, A. W., Drutman, S. B., Jinwala, F., Bahjat, K. S. & Bhardwaj, N. PLoS ONE 5, e11144 (2010).
Avigan, D. E. et al. J. Immunotherapy 30, 749–761 (2007).
Balan, S. et al. J. Immunol. 193, 1622–1635 (2014).
Wang, J., Lau, K. Y., Jung, J., Ravindran, P. & Barrat, F. J. Eur. J. Immunol. 44, 1130–1136 (2014).
Eisenberg, E. & Levanon, E. Y. Trends Genet. 29, 569–574 (2013).
Sawasdikosol, S., Zha, R., Yang, B. & Burakoff, S. Immunologic Res. 54, 262–265 (2012).
Hobo, W. et al. Blood 116, 4501–4511 (2010).
Pen, J. J. et al. Gene Therapy 21, 262–271 (2014).
Wilgenhof, S. et al. J. Clin. Oncol. 34, 1330–1338 (2016).
Wilgenhof, S. et al. Cancer Immunol. Immunotherapy 64, 381–388 (2015).
Wilgenhof, S. et al. Ann. Oncol. 24, 2686–2693 (2013).
Daenthanasanmak, A. et al. Mol. Therapy Methods Clin. Dev. 1, 14060 (2015).
Kreiter, S. et al. Cancer Res. 70, 9031–9040 (2010).
Kheshtchin, N. et al. Cancer Immunol. Immunotherapy 65, 1159–1167 (2016).
Acknowledgements
This work was supported by the National Institutes of Health grants RO1CA201189, R01CA180913 and R01AI081848, the Cancer Research Institute and the Melanoma Research Alliance. N.B. is a member of the Parker Institute for Cancer Immunotherapy, which supports the Icahn School of Medicine at Mount Sinai, NY, Cancer Immunotherapy Program.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
N.B. is on the senior advisory board of Check Point Sciences, Curevac, Neon and Inception, and a consultant for Genentech. All potential conflicts of interest are being managed by the Conflict of Interest Office, Icahn School of Medicine at Mount Sinai. M.S., S.B. and V.R. declare no competing interests.
Rights and permissions
About this article
Cite this article
Saxena, M., Balan, S., Roudko, V. et al. Towards superior dendritic-cell vaccines for cancer therapy. Nat Biomed Eng 2, 341–346 (2018). https://doi.org/10.1038/s41551-018-0250-x
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41551-018-0250-x
This article is cited by
-
Development of dendritic cell loaded MAGE-A2 long peptide; a potential target for tumor-specific T cell-mediated prostate cancer immunotherapy
Cancer Cell International (2023)
-
Close the cancer–immunity cycle by integrating lipid nanoparticle–mRNA formulations and dendritic cell therapy
Nature Nanotechnology (2023)
-
Biomimetic nanovaccine-mediated multivalent IL-15 self-transpresentation (MIST) for potent and safe cancer immunotherapy
Nature Communications (2023)
-
Metabolic glycan labeling immobilizes dendritic cell membrane and enhances antitumor efficacy of dendritic cell vaccine
Nature Communications (2023)
-
Rescue of dendritic cells from glycolysis inhibition improves cancer immunotherapy in mice
Nature Communications (2023)